title: Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.
abstract: Current seasonal influenza vaccines have reduced immunogenicity and are of suboptimal efficacy in older adults. We have previously shown that the novel candidate vaccine MVA-NP+M1 is able to boost memory T cell responses in adults aged 50-85 years. Preclinical studies have demonstrated that viral vectored vaccines can act as adjuvants when coadministered with protein-based vaccines. We have conducted a phase I clinical trial to compare the coadministration of seasonal influenza vaccine and MVA-NP+M1 with seasonal influenza vaccine alone in adults aged 50 years and above. This combination of vaccines was safe and well tolerated. T cell responses to internal influenza proteins were boosted to significantly higher levels in the group receiving MVA-NP+M1 compared with the group receiving seasonal influenza vaccine alone. Rates of seroprotection and seroconversion against the three vaccine strains were similar in both groups; however, there was a significant increase in the geometric mean titer ratio for the H3N2 component of seasonal influenza vaccine in the coadministration group. While some vaccine combinations result in immune interference, the coadministration of MVA-NP+M1 alongside seasonal influenza vaccine is shown here to increase some influenza strain-specific antibody responses and boost memory T cells capable of recognizing a range of influenza A subtypes.
authors.affiliation: The Jenner Institute, University of Oxford, Oxford, UK.
authors.forename: Richard D
authors.initials: RD
authors.lastname: Antrobus
authors.affiliation: The Jenner Institute, University of Oxford, Oxford, UK.
authors.forename: Tamara K
authors.initials: TK
authors.lastname: Berthoud
authors.affiliation: The Jenner Institute, University of Oxford, Oxford, UK.
authors.forename: Caitlin E
authors.initials: CE
authors.lastname: Mullarkey
authors.affiliation: Respiratory Virus Unit, Public Health England, London, UK.
authors.forename: Katja
authors.initials: K
authors.lastname: Hoschler
authors.affiliation: The Jenner Institute, University of Oxford, Oxford, UK.
authors.forename: Lynda
authors.initials: L
authors.lastname: Coughlan
authors.affiliation: Respiratory Virus Unit, Public Health England, London, UK.
authors.forename: Maria
authors.initials: M
authors.lastname: Zambon
authors.affiliation: The Jenner Institute, University of Oxford, Oxford, UK.
authors.forename: Adrian V S
authors.initials: AV
authors.lastname: Hill
authors.affiliation: The Jenner Institute, University of Oxford, Oxford, UK.
authors.forename: Sarah C
authors.initials: SC
authors.lastname: Gilbert
mesh_terms: D000368:Aged; D000914:Antibodies, Viral / Q000276:immunology; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D007251:Influenza, Human / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D019444:Vaccines, DNA; D014758:Viral Core Proteins / Q000276:immunology*; D014763:Viral Matrix Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines; C488936:M1 protein, Influenza A virus; C560489:MVA vaccine; D019444:Vaccines, DNA; D014758:Viral Core Proteins; D014763:Viral Matrix Proteins; D014765:Viral Vaccines